Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT for Cognitive Impairment in Schizophrenia
2025-523060-20-00Phase 3Withdrawn
- Sponsor
- European Group for Research in Schizophrenia
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of xanomeline in schizophrenia, sponsored by European Group for Research in Schizophrenia. Primary endpoint: Change from baseline to week 24 in the BACS composite cognitive score. Planned start Mar 2026; status: withdrawn.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2025-523060-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523060-20-00.